Skip to main content

21-01-2020 | Oncology | News | Article


Apalutamide–ADT indication expanded in Europe

Lynda Williams

medwireNews: Men in Europe with metastatic castration-sensitive prostate cancer may now be treated with the anti-androgen agent apalutamide during androgen deprivation therapy (ADT).

This indication’s positive opinion by the EMA reflects results from the TITAN trial showing progression-free and overall survival benefits with the combination.

The EMA previously granted approval for use of the combination in men with nonmetastatic castration-resistant prostate cancer at high risk for distant disease based on findings from the SPARTAN trial, and both indications have already been approved by the US FDA.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature group

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits